NewGenIvf Group Limited
NIVF · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 5.8% | -13.6% | 44.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 33.6% | 32.7% | 25.9% | 24.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | $0 | -$0 | $0 |
| % Margin | -21.4% | 0.8% | -8.5% | 4.8% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$0 | $0 | $0 | $0 |
| Tax Expense | -$0 | $0 | $0 | $0 |
| Net Income | -$0 | $0 | $0 | -$0 |
| % Margin | -9.7% | 2.5% | 7.7% | -0% |
| EPS | -115.25 | 64.25 | 323 | -0.025 |
| % Growth | -279.4% | -80.1% | 1,292,100% | – |
| EPS Diluted | -115.25 | 64.25 | 323 | -0.025 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 0.4% | 7.5% | 12.2% | 14.3% |